| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| Other Sizes |
|
Purity: ≥98%
Lurasidone HCl (SM-13496; SM 13496; trade name Latuda), the hydrochloride salt of Lurasidone, is an atypical antipsychotic drug that has been approved for the treatment of schizophrenia and bipolar disorder. It acts by potently inhibiting Dopamine D2, 5-HT2A, 5-HT7, 5-HT1A and noradrenaline α2C with IC50s of 1.68 nM, 2.03 nM, 0.495 nM, 6.75 nM and 10.8 nM, respectively.
| Targets |
5-HT7 Receptor ( IC50 = 0.495 nM ); 5-HT1A Receptor ( IC50 = 6.75 nM ); D2 Receptor ( IC50 = 1.68 nM )
|
|
|---|---|---|
| ln Vitro |
|
|
| ln Vivo |
|
|
| Animal Protocol |
|
|
| References |
| Molecular Formula |
C28H37CLN4O2S
|
|---|---|
| Molecular Weight |
529.14
|
| Exact Mass |
528.23
|
| Elemental Analysis |
C, 63.56; H, 7.05; Cl, 6.70; N, 10.59; O, 6.05; S, 6.06
|
| CAS # |
367514-88-3
|
| Related CAS # |
Lurasidone; 367514-87-2; Lurasidone metabolite 14326 hydrochloride; Lurasidone-d8 hydrochloride; Lurasidone Metabolite 14283-d8; 2070009-43-5; Lurasidone metabolite 14326; 186204-33-1; Lurasidone Metabolite 14326-d8
|
| Appearance |
Solid powder
|
| SMILES |
C1CC[C@H]([C@@H](C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)[C@H]6[C@@H]7CC[C@@H](C7)[C@H]6C5=O.Cl
|
| InChi Key |
NEKCRUIRPWNMLK-SCIYSFAVSA-N
|
| InChi Code |
InChI=1S/C28H36N4O2S.ClH/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26;/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2;1H/t18-,19+,20-,21-,24+,25-;/m0./s1
|
| Chemical Name |
(1S,2R,6S,7R)-4-[[(1R,2R)-2-[[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl]cyclohexyl]methyl]-4-azatricyclo[5.2.1.02,6]decane-3,5-dione;hydrochloride
|
| Synonyms |
SM13496; Lurasidone HCl; SM-13496; SM 13496; trade name Latuda
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.67 mg/mL (1.27 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 6.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.67 mg/mL (1.27 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 6.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8899 mL | 9.4493 mL | 18.8986 mL | |
| 5 mM | 0.3780 mL | 1.8899 mL | 3.7797 mL | |
| 10 mM | 0.1890 mL | 0.9449 mL | 1.8899 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05213143 | Active Recruiting |
Drug: Lurasidone | Schizophrenia | Sumitomo Pharma (Suzhou) Co., Ltd. | December 30, 2021 | Phase 4 |
| NCT03395392 | Active Recruiting |
Drug: NRX-101 Drug: Lurasidone HCl |
Bipolar Depression Suicidal Ideation and Behavior |
Second Affiliated Hospital of Guangzhou Medical University |
May 12, 2022 | Phase 2 Phase 3 |
| NCT03396068 | Active Recruiting |
Drug: Lurasidone HCl Drug: NRX-101 |
Bipolar Depression Suicidal Ideation |
NeuroRx, Inc. | December 1, 2019 | Phase 3 |
| NCT02731612 | Recruiting | Drug: lurasidone Drug: Placebo |
Bipolar Disorder | Nazlin Walji | May 8, 2017 | Phase 3 |
| NCT05351736 | Recruiting | Drug: Lurasidone | Schizophrenia | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico |
January 26, 2022 | Phase 4 |
|
|---|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
